CpG-ODN increases the release of VEGF in a mouse model of lung carcinoma

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2815-2822

  Sorrentino, Rosalinda ^a   Morello, Silvana ^a   Giordano, Maria Grazia ^a   Arra, Claudio ^b   Maiolino, Piera ^b   Adcock, Ian M ^c   Pinto, Aldo ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

angiogenesis; CpG; lung carcinoma; toll like receptors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SINGLE DRUG DOSE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, LEWIS LUNG; CPG ISLANDS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955408975     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25626     Document Type: Article

References (23)

1. Jahrsdorfer B, Weiner GJ,. CpG oligodeoxynucleotides as immunotherapy in cancer. Cancer Ther 2008; 3: 27-32. (Pubitemid 351410539)
2. Igney FH, Krammer PH,. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leuk Biol 2002; 71: 7-20.
3. Rakoff-Nahoum S, Medzhitov R,. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63.
4. Kluwe J, Mencin A, Schwabe RF,. Toll like receptors, wound healing and carcinogenesis. J Mol Med 2009; 87: 125-38.
5. Meyer T, Stockfleth E,. Clinical investigations of toll-like receptor agonists. Expert Opin Investig Drugs 2008; 17: 1051-65.
6. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T,. Human lung cancer cells express functionally active toll-like receptor 9. Respir Res 2005; 6: 1.
7. Krieg AM,. Development of TLR9 agonist for cancer therapy. J Clin Invest 2007; 117: 1184-94 (Pubitemid 46718403)
8. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H, Wen Z,. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 2009; 15: 623-30.
9. Kalluri R, Zeisberg M,. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-402
10. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA,. Cancer associated fibroblasts promote tumour growth and metastasis by modulating the tumour immune microenvironment in a 4T1 breast cancer model. Plos One 2009; 4: e7965.
11. Herbst RS, Sandler A,. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 2008; 13: 1166-76.
12. Pau EC, Arias FC, Pelaez EC, Trueba IM, Hernández IS, Molina GM, Balsalobre RM, López SS, Gómez-Pinillos A, Toledo Lobo MD,. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 2010; 28: 393-8.
13. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M,. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
14. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM,. T Cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-8. (Pubitemid 29501270)
15. Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, Shurin GV,. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007; 13: 5455-62. (Pubitemid 47510373)
16. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H,. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009; 206: 1457-64.
17. Greenberg JI, Cheresh DA,. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 2009; 9: 1347-56.
18. Sorrentino R, Morello S, Pinto A,. Plasmacytoid and lung-associated inflammation. Recent Pat Inflam Allergy Drug Discovery 2010; 4: 138-43.
19. Ishikawa H, Tsuyama N, Liu S, Abroun S, Li FJ, Otsuyama K, Zheng X, Ma Z, Maki Y, Iqbal MS, Obata M, Kawano MM,. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 2005; 24: 6328-32. (Pubitemid 43080056)
20. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27: 925-32
21. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ, Jr, Yokota SJ, Bankert RB,. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 2007; 178: 5552-62. (Pubitemid 46674350)
22. Chapoval SP, Lee CG, Tang C, Keegan AD, Cohn L, Bottomly K, Elias JA,. Lung vascular endothelial growth factor expression induces local myeloid dendritic cell activation. Clin Immunol 2009; 132: 371-84.
23. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM,. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010; 11: 373-82.